HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Takeru Kusumoto Selected Research

relugolix

10/2021Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial.
1/2021Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results.
1/2021Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Takeru Kusumoto Research Topics

Disease

3Menorrhagia
10/2021 - 01/2021
2Pelvic Pain
01/2021 - 01/2021
2Endometriosis
01/2021 - 01/2021
2Metrorrhagia (Spotting)
01/2021 - 01/2021
2Pain (Aches)
01/2021 - 01/2021
1Leiomyoma (Uterine Fibroids)
10/2021
1Menstruation Disturbances
01/2021

Drug/Important Bio-Agent (IBA)

3relugolixIBA
10/2021 - 01/2021
3LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)IBA
10/2021 - 01/2021
2Gonadotropin-Releasing Hormone (GnRH)FDA Link
10/2021 - 01/2021
2Leuprolide (Lupron)FDA LinkGeneric
01/2021 - 01/2021

Therapy/Procedure

1Oral Administration
01/2021